Innate Pharma Q3 2026 Business Update and Financial Results - INNATE PHARMA SA

Explicit Guidance:

• No explicit financial guidance (revenue, earnings, margins, capex, cash flow, tax rate, dividends, or buybacks) was provided for future periods.
• Cash Horizon: Anticipated cash runway extends through the end of Q1 2028, based on a cash position of $96.8 million as of September 30, 2026.

Business-Segment Outlook:

• Lectutamab (Lakutumab):
  • Development: Phase 3 Telemat-3 study initiated; first patient dosing expected in Q1 2027.
  • Regulatory: Filing for accelerated approval in Cutaneous T-Cell Lymphoma (CTCL), specifically "Cesarean syndrome" (likely Mycosis Fungoides), planned for the second half of 2027, with potential approval in the first half of 2028.
  • Commercial Rights: Upon potential accelerated approval, partner SOBI receives global commercial rights. Following positive Phase 3 results, SOBI may obtain full global development rights.
  • Pipeline Milestones: Up to $40 million in near-term milestones for CTCL regulatory events and $465 million in milestones if SOBI exercises the option for full rights; double-digit royalties on net sales.
• IPH-4502 (Nectin-4 ADC):
  • Clinical Data: Phase 1 dose escalation data to be presented at the EORTC-NCI-AACR Symposium on November 18, 2026.
  • Safety/Efficacy: Preliminary antitumor activity (objective responses) observed in heavily pre-treated patients with a favorable safety profile; activity noted in urothelial, non-small cell lung, and head and neck cancers.
  • Next Steps: Protocol for next steps to be discussed at the November 18, 2026 KOL event; further details expected on presentation day.
• Monalizumab:
  • STIG-9 Trial (NSCLC): Enrollment complete for the Phase 3 trial in unresectable stage III NSCLC.
  • Readout: Phase 3 data expected in the first half of 2027 (delayed from prior expectations due to event-driven nature of the study; trial led by AstraZeneca).
• Preclinical/Next-Gen ADC:
  • Building a pipeline of ADC candidates using proprietary stable linker technology, focusing on: dual-targeted bispecifics, bispecifics with enhanced internalization, and dual-payload ADCs.

Market and Competitive Outlook:

• Nectin-4 ADC Landscape: IPH-4502 is differentiated via a novel linker and non-overlapping epitope binding compared to competitor Enfortumab vedotin, aiming to address limitations of first-generation Nectin-4 ADCs (tumor antigen heterogeneity, low expression, resistance).
• Head and Neck Opportunity: Management acknowledges recent successes with EGFR bispecifics but notes limited specific data for IPH-4502 in head and neck cancer; no specific market share or pricing targets provided for this segment.
• NSCLC Competition: STIG-9 trial compares Monalizumab + Durvalumab against Durvalumab alone and Durvalumab + another competitor; primary endpoint is progression-free survival.

Macro / Industry Outlook:

• Regulatory Environment: Management expects to utilize FDA accelerated approval pathways for CTCL (Lectutamab) based on existing Phase 2 data.
• Partnership Economics: No changes to macro assumptions mentioned; reliance on partner execution (SOBI for CTCL, AstraZeneca for NSCLC) for global commercialization and milestone realization.

Strategic Initiatives:

• Strategic Partnerships:
  • SOBI: Partnership effective immediately; $75 million upfront payment received; SOBI to lead Phase 3 for Lectutamab in CTCL.
  • AstraZeneca: Total receipts of $450 million to date; up to $825 million in potential milestones; 50% profit sharing in Europe and double-digit royalties outside Europe for Monalizumab.
• Catalyst Timeline:
  • Nov 18, 2026: Presentation of IPH-4502 Phase 1 data (Barcelona).
  • Q1 2027: First patient dosing for Lectutamab Telemat-3.
  • First Half 2027: Monalizumab Phase 3 readout (STIG-9).
• Leadership Change: CFO Frederic Lombard departing December 2026; search for successor initiated.

Risks and Headwinds to Outlook:

• Trial Timing Risks: Delays in clinical readouts (specifically STIG-9/Monalizumab) attributed to the event-driven nature of the study; management cautions against speculating on data quality based on timing delays (could indicate over-performing experimental or control arms).
• Regulatory Uncertainty: Accelerated approval and full regulatory approval are contingent on successful Phase 3 results and FDA review.
• Execution Risk: Reliance on partners (SOBI, AstraZeneca) for study execution and commercialization; potential for milestone payments to not be reached if regulatory/development targets are missed.
• Clinical Risk: IPH-4502 safety and efficacy in specific tumor types (e.g., head and neck) remains unproven in larger datasets.

Management Tone on the Future:

• Confidence: Cautiously optimistic; emphasizes "several important near-term catalysts" and a "strengthened financial position" to support execution.
• Hedges: Frequent use of "expected," "projected," and "under current expectations." Explicit caution advised regarding interpreting clinical trial delays as signals of efficacy or safety.
• Changes vs. Prior: Acknowledges a delay in the Monalizumab Phase 3 readout (now H1 2027 vs. implied earlier timing), attributing it to standard event-driven variability rather than negative data trends.

Miscellaneous:

• Financial Updates: No specific revenue guidance provided, though future upside identified via $40M CTCL milestones and $465M potential partnership option exercise, plus $75M upfront already received from SOBI.
• Investor Events: Virtual/in-person event scheduled for November 18, 2026, in London (1 p.m. GMT / 11 a.m. ET) regarding IPH-4502 data.